Boehringer takes alteplase to phase 3 for COVID, but drops antibodyBoehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its Share XBoehringer takes alteplase to phase 3 for COVID, but drops antibodyhttps://pharmaphorum.com/news/boehringer-takes-alteplase-to-phase-3-for-covid-but-drops-antibody/
